US20100029973A1 - Fatty acid analogues for equilibrating bone mineral density - Google Patents

Fatty acid analogues for equilibrating bone mineral density Download PDF

Info

Publication number: US20100029973A1
Authority: US; United States
Prior art keywords: group; atom; carbon atoms; bone; unsaturated
Prior art date: 2005-07-18
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

US11/989,004

Other languages

English (en)

Inventor

Rolf Berge

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Thia Medica AS

Original Assignee

Thia Medica AS

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-07-18

Filing date

2006-07-10

Publication date

2010-02-04

2006-07-10 Application filed by Thia Medica AS filed Critical Thia Medica AS

2009-05-06 Assigned to THIA MEDICA AS reassignment THIA MEDICA AS ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BERGE, ROLF

2010-02-04 Publication of US20100029973A1 publication Critical patent/US20100029973A1/en

Status Abandoned legal-status Critical Current

Links

210000000988 bone and bone Anatomy 0.000 title claims abstract description 45
229910052500 inorganic mineral Inorganic materials 0.000 title claims abstract description 7
239000011707 mineral Substances 0.000 title claims abstract description 7
150000004665 fatty acids Chemical class 0.000 title abstract description 69
235000014113 dietary fatty acids Nutrition 0.000 title abstract description 68
239000000194 fatty acid Substances 0.000 title abstract description 68
229930195729 fatty acid Natural products 0.000 title abstract description 68
150000001875 compounds Chemical class 0.000 claims abstract description 75
208000006386 Bone Resorption Diseases 0.000 claims abstract description 51
230000024279 bone resorption Effects 0.000 claims abstract description 50
230000003247 decreasing effect Effects 0.000 claims abstract description 14
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 11
238000011282 treatment Methods 0.000 claims abstract description 10
230000002265 prevention Effects 0.000 claims abstract description 6
125000004430 oxygen atom Chemical group O* 0.000 claims description 41
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 37
125000004432 carbon atom Chemical group C* 0.000 claims description 37
125000000217 alkyl group Chemical group 0.000 claims description 35
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 31
229920006395 saturated elastomer Polymers 0.000 claims description 30
208000001132 Osteoporosis Diseases 0.000 claims description 29
IPBCWPPBAWQYOO-UHFFFAOYSA-N 2-(tetradecylthio)acetic acid Chemical compound CCCCCCCCCCCCCCSCC(O)=O IPBCWPPBAWQYOO-UHFFFAOYSA-N 0.000 claims description 28
BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical group [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 26
229910052711 selenium Inorganic materials 0.000 claims description 26
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims description 18
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 17
125000005842 heteroatom Chemical group 0.000 claims description 14
206010065687 Bone loss Diseases 0.000 claims description 10
SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims description 9
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 9
OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims description 9
229960001231 choline Drugs 0.000 claims description 9
CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims description 9
229960000367 inositol Drugs 0.000 claims description 9
150000003839 salts Chemical class 0.000 claims description 9
CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims description 9
239000000651 prodrug Substances 0.000 claims description 8
229940002612 prodrug Drugs 0.000 claims description 8
208000020084 Bone disease Diseases 0.000 claims description 7
239000003018 immunosuppressive agent Substances 0.000 claims description 6
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 5
208000010191 Osteitis Deformans Diseases 0.000 claims description 5
208000027868 Paget disease Diseases 0.000 claims description 5
230000006378 damage Effects 0.000 claims description 5
229960002897 heparin Drugs 0.000 claims description 5
229920000669 heparin Polymers 0.000 claims description 5
229960003444 immunosuppressant agent Drugs 0.000 claims description 5
208000027202 mammary Paget disease Diseases 0.000 claims description 5
201000008968 osteosarcoma Diseases 0.000 claims description 5
VZNVUJNOJIDOAP-UHFFFAOYSA-N 14-ethylsulfanyltetradec-2-yne Chemical compound CCSCCCCCCCCCCCC#CC VZNVUJNOJIDOAP-UHFFFAOYSA-N 0.000 claims description 4
LUQGQZIVDLUXLE-UHFFFAOYSA-N CCCCCCCCCCCCCCCC(O)=[Se] Chemical compound CCCCCCCCCCCCCCCC(O)=[Se] LUQGQZIVDLUXLE-UHFFFAOYSA-N 0.000 claims description 4
208000029725 Metabolic bone disease Diseases 0.000 claims description 4
206010047623 Vitamin C deficiency Diseases 0.000 claims description 4
230000001861 immunosuppressant effect Effects 0.000 claims description 4
208000010233 scurvy Diseases 0.000 claims description 4
201000002980 Hyperparathyroidism Diseases 0.000 claims description 3
208000034578 Multiple myelomas Diseases 0.000 claims description 3
206010049088 Osteopenia Diseases 0.000 claims description 3
206010035226 Plasma cell myeloma Diseases 0.000 claims description 3
208000027418 Wounds and injury Diseases 0.000 claims description 3
208000014674 injury Diseases 0.000 claims description 3
230000000366 juvenile effect Effects 0.000 claims description 3
208000028169 periodontal disease Diseases 0.000 claims description 3
201000003617 glucocorticoid-induced osteoporosis Diseases 0.000 claims description 2
238000002360 preparation method Methods 0.000 abstract description 6
238000007254 oxidation reaction Methods 0.000 description 35
230000000694 effects Effects 0.000 description 30
102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 17
108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 17
230000007423 decrease Effects 0.000 description 17
102000023984 PPAR alpha Human genes 0.000 description 16
238000000034 method Methods 0.000 description 16
HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 16
230000011164 ossification Effects 0.000 description 13
210000000963 osteoblast Anatomy 0.000 description 13
210000002997 osteoclast Anatomy 0.000 description 13
108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 description 12
108010016731 PPAR gamma Proteins 0.000 description 11
102000000536 PPAR gamma Human genes 0.000 description 10
241000700159 Rattus Species 0.000 description 9
150000002632 lipids Chemical class 0.000 description 9
0 [1*]OCC(CO[3*])O[2*] Chemical compound [1*]OCC(CO[3*])O[2*] 0.000 description 8
230000015572 biosynthetic process Effects 0.000 description 8
YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 8
229960002297 fenofibrate Drugs 0.000 description 8
238000001727 in vivo Methods 0.000 description 8
229960005095 pioglitazone Drugs 0.000 description 8
SZRPDCCEHVWOJX-UHFFFAOYSA-N pirinixic acid Chemical compound CC1=CC=CC(NC=2N=C(SCC(O)=O)N=C(Cl)C=2)=C1C SZRPDCCEHVWOJX-UHFFFAOYSA-N 0.000 description 8
229940080774 Peroxisome proliferator-activated receptor gamma agonist Drugs 0.000 description 7
239000000556 agonist Substances 0.000 description 7
230000004071 biological effect Effects 0.000 description 7
230000037182 bone density Effects 0.000 description 7
239000011575 calcium Substances 0.000 description 7
230000015556 catabolic process Effects 0.000 description 7
201000010099 disease Diseases 0.000 description 7
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
235000011187 glycerol Nutrition 0.000 description 7
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 6
102000008108 Osteoprotegerin Human genes 0.000 description 6
108010035042 Osteoprotegerin Proteins 0.000 description 6
230000004097 bone metabolism Effects 0.000 description 6
229910052791 calcium Inorganic materials 0.000 description 6
239000003862 glucocorticoid Substances 0.000 description 6
XXUPLYBCNPLTIW-UHFFFAOYSA-N octadec-7-ynoic acid Chemical compound CCCCCCCCCCC#CCCCCCC(O)=O XXUPLYBCNPLTIW-UHFFFAOYSA-N 0.000 description 6
150000003904 phospholipids Chemical class 0.000 description 6
230000000638 stimulation Effects 0.000 description 6
229940037128 systemic glucocorticoids Drugs 0.000 description 6
241001465754 Metazoa Species 0.000 description 5
239000005864 Sulphur Substances 0.000 description 5
230000037396 body weight Effects 0.000 description 5
230000004069 differentiation Effects 0.000 description 5
239000003550 marker Substances 0.000 description 5
239000000203 mixture Substances 0.000 description 5
230000037361 pathway Effects 0.000 description 5
108090000623 proteins and genes Proteins 0.000 description 5
235000004400 serine Nutrition 0.000 description 5
210000001519 tissue Anatomy 0.000 description 5
DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 5
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
102000012422 Collagen Type I Human genes 0.000 description 4
108010022452 Collagen Type I Proteins 0.000 description 4
108010028924 PPAR alpha Proteins 0.000 description 4
239000012190 activator Substances 0.000 description 4
238000006731 degradation reaction Methods 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
239000003446 ligand Substances 0.000 description 4
210000004185 liver Anatomy 0.000 description 4
239000011159 matrix material Substances 0.000 description 4
238000005259 measurement Methods 0.000 description 4
-1 mono- Chemical class 0.000 description 4
230000003647 oxidation Effects 0.000 description 4
239000000243 solution Substances 0.000 description 4
238000012360 testing method Methods 0.000 description 4
238000002604 ultrasonography Methods 0.000 description 4
206010017076 Fracture Diseases 0.000 description 3
LCYXYLLJXMAEMT-SAXRGWBVSA-N Pyridinoline Chemical compound OC(=O)[C@@H](N)CCC1=C[N+](C[C@H](O)CC[C@H](N)C([O-])=O)=CC(O)=C1C[C@H](N)C(O)=O LCYXYLLJXMAEMT-SAXRGWBVSA-N 0.000 description 3
230000000903 blocking effect Effects 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000008280 blood Substances 0.000 description 3
210000004271 bone marrow stromal cell Anatomy 0.000 description 3
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
210000004027 cell Anatomy 0.000 description 3
230000002596 correlated effect Effects 0.000 description 3
230000006735 deficit Effects 0.000 description 3
239000007857 degradation product Substances 0.000 description 3
239000003814 drug Substances 0.000 description 3
238000009472 formulation Methods 0.000 description 3
230000002209 hydrophobic effect Effects 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
230000004072 osteoblast differentiation Effects 0.000 description 3
229910052760 oxygen Inorganic materials 0.000 description 3
239000000825 pharmaceutical preparation Substances 0.000 description 3
150000008104 phosphatidylethanolamines Chemical class 0.000 description 3
150000003905 phosphatidylinositols Chemical class 0.000 description 3
239000000047 product Substances 0.000 description 3
230000009467 reduction Effects 0.000 description 3
238000011160 research Methods 0.000 description 3
239000000126 substance Substances 0.000 description 3
238000002560 therapeutic procedure Methods 0.000 description 3
150000003626 triacylglycerols Chemical class 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
208000010392 Bone Fractures Diseases 0.000 description 2
102000008186 Collagen Human genes 0.000 description 2
108010035532 Collagen Proteins 0.000 description 2
ZAHDXEIQWWLQQL-IHRRRGAJSA-N Deoxypyridinoline Chemical compound OC(=O)[C@@H](N)CCCC[N+]1=CC(O)=C(C[C@H](N)C([O-])=O)C(CC[C@H](N)C(O)=O)=C1 ZAHDXEIQWWLQQL-IHRRRGAJSA-N 0.000 description 2
MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical group O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 2
ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 2
102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
108010015181 PPAR delta Proteins 0.000 description 2
108010044210 PPAR-beta Proteins 0.000 description 2
102000014128 RANK Ligand Human genes 0.000 description 2
108010025832 RANK Ligand Proteins 0.000 description 2
ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
230000003213 activating effect Effects 0.000 description 2
210000001789 adipocyte Anatomy 0.000 description 2
230000032683 aging Effects 0.000 description 2
150000001299 aldehydes Chemical class 0.000 description 2
AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 2
230000004075 alteration Effects 0.000 description 2
235000001014 amino acid Nutrition 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
210000002449 bone cell Anatomy 0.000 description 2
230000010072 bone remodeling Effects 0.000 description 2
230000008416 bone turnover Effects 0.000 description 2
239000000872 buffer Substances 0.000 description 2
229910052799 carbon Inorganic materials 0.000 description 2
239000000969 carrier Substances 0.000 description 2
230000008859 change Effects 0.000 description 2
229920001436 collagen Polymers 0.000 description 2
230000000875 corresponding effect Effects 0.000 description 2
DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
238000001739 density measurement Methods 0.000 description 2
FRKBLBQTSTUKOV-UHFFFAOYSA-N diphosphatidyl glycerol Natural products OP(O)(=O)OCC(OP(O)(O)=O)COP(O)(O)=O FRKBLBQTSTUKOV-UHFFFAOYSA-N 0.000 description 2
PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
229940011871 estrogen Drugs 0.000 description 2
239000000262 estrogen Substances 0.000 description 2
235000021588 free fatty acids Nutrition 0.000 description 2
230000006870 function Effects 0.000 description 2
150000002327 glycerophospholipids Chemical class 0.000 description 2
IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
229960002591 hydroxyproline Drugs 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
238000003780 insertion Methods 0.000 description 2
230000037431 insertion Effects 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
239000007788 liquid Substances 0.000 description 2
210000002540 macrophage Anatomy 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
230000035800 maturation Effects 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
230000009245 menopause Effects 0.000 description 2
210000003470 mitochondria Anatomy 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
239000001301 oxygen Substances 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
230000008569 process Effects 0.000 description 2
210000004206 promonocyte Anatomy 0.000 description 2
235000018102 proteins Nutrition 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
238000012216 screening Methods 0.000 description 2
230000035945 sensitivity Effects 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
238000006467 substitution reaction Methods 0.000 description 2
150000005846 sugar alcohols Polymers 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 2
238000002054 transplantation Methods 0.000 description 2
210000002700 urine Anatomy 0.000 description 2
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 1
241001502050 Acis Species 0.000 description 1
102000007698 Alcohol dehydrogenase Human genes 0.000 description 1
108010021809 Alcohol dehydrogenase Proteins 0.000 description 1
102000005369 Aldehyde Dehydrogenase Human genes 0.000 description 1
108020002663 Aldehyde Dehydrogenase Proteins 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
206010061728 Bone lesion Diseases 0.000 description 1
YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
108010004103 Chylomicrons Proteins 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 1
108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
229920001353 Dextrin Polymers 0.000 description 1
239000004375 Dextrin Substances 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
239000001828 Gelatine Substances 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
241001481828 Glyptocephalus cynoglossus Species 0.000 description 1
206010020100 Hip fracture Diseases 0.000 description 1
241000282412 Homo Species 0.000 description 1
206010020850 Hyperthyroidism Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
238000012404 In vitro experiment Methods 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
108090001030 Lipoproteins Proteins 0.000 description 1
102000004895 Lipoproteins Human genes 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
229920003091 Methocel™ Polymers 0.000 description 1
CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
208000012902 Nervous system disease Diseases 0.000 description 1
208000025966 Neurological disease Diseases 0.000 description 1
102000004067 Osteocalcin Human genes 0.000 description 1
108090000573 Osteocalcin Proteins 0.000 description 1
208000001164 Osteoporotic Fractures Diseases 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
235000021314 Palmitic acid Nutrition 0.000 description 1
241000255964 Pieridae Species 0.000 description 1
208000005770 Secondary Hyperparathyroidism Diseases 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
229930003268 Vitamin C Natural products 0.000 description 1
230000009471 action Effects 0.000 description 1
125000004423 acyloxy group Chemical group 0.000 description 1
239000000654 additive Substances 0.000 description 1
210000000577 adipose tissue Anatomy 0.000 description 1
125000002009 alkene group Chemical group 0.000 description 1
150000001345 alkine derivatives Chemical group 0.000 description 1
125000003545 alkoxy group Chemical group 0.000 description 1
125000004414 alkyl thio group Chemical group 0.000 description 1
150000001414 amino alcohols Chemical class 0.000 description 1
239000003098 androgen Substances 0.000 description 1
210000003423 ankle Anatomy 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
235000009697 arginine Nutrition 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
238000003556 assay Methods 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
230000008827 biological function Effects 0.000 description 1
230000031018 biological processes and functions Effects 0.000 description 1
239000006227 byproduct Substances 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
230000002308 calcification Effects 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
239000002775 capsule Substances 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
150000001721 carbon Chemical group 0.000 description 1
239000012876 carrier material Substances 0.000 description 1
230000024245 cell differentiation Effects 0.000 description 1
230000003915 cell function Effects 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
230000019522 cellular metabolic process Effects 0.000 description 1
230000004700 cellular uptake Effects 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
229940106189 ceramide Drugs 0.000 description 1
ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
229930183167 cerebroside Natural products 0.000 description 1
150000001784 cerebrosides Chemical class 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
229940096422 collagen type i Drugs 0.000 description 1
230000001332 colony forming effect Effects 0.000 description 1
238000002591 computed tomography Methods 0.000 description 1
210000002808 connective tissue Anatomy 0.000 description 1
230000001054 cortical effect Effects 0.000 description 1
229940109239 creatinine Drugs 0.000 description 1
230000002950 deficient Effects 0.000 description 1
239000000841 delta opiate receptor agonist Substances 0.000 description 1
238000005115 demineralization Methods 0.000 description 1
230000002328 demineralizing effect Effects 0.000 description 1
230000006866 deterioration Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
235000019425 dextrin Nutrition 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
150000001982 diacylglycerols Chemical class 0.000 description 1
150000002016 disaccharides Chemical class 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
239000008298 dragée Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
230000004821 effect on bone Effects 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
230000032050 esterification Effects 0.000 description 1
238000005886 esterification reaction Methods 0.000 description 1
229940031098 ethanolamine Drugs 0.000 description 1
LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
229940093471 ethyl oleate Drugs 0.000 description 1
230000029142 excretion Effects 0.000 description 1
239000012467 final product Substances 0.000 description 1
230000004927 fusion Effects 0.000 description 1
238000003304 gavage Methods 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
239000008103 glucose Substances 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
229960005150 glycerol Drugs 0.000 description 1
230000012010 growth Effects 0.000 description 1
229940093915 gynecological organic acid Drugs 0.000 description 1
230000005802 health problem Effects 0.000 description 1
230000002607 hemopoietic effect Effects 0.000 description 1
235000009200 high fat diet Nutrition 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
230000003054 hormonal effect Effects 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
229920001477 hydrophilic polymer Polymers 0.000 description 1
125000004356 hydroxy functional group Chemical group O* 0.000 description 1
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
230000028993 immune response Effects 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
229940072221 immunoglobulins Drugs 0.000 description 1
229940124589 immunosuppressive drug Drugs 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
238000001361 intraarterial administration Methods 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
230000001788 irregular Effects 0.000 description 1
239000008101 lactose Substances 0.000 description 1
230000004322 lipid homeostasis Effects 0.000 description 1
230000037356 lipid metabolism Effects 0.000 description 1
239000002502 liposome Substances 0.000 description 1
150000004668 long chain fatty acids Chemical class 0.000 description 1
230000007774 longterm Effects 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
229940057948 magnesium stearate Drugs 0.000 description 1
238000002595 magnetic resonance imaging Methods 0.000 description 1
230000036210 malignancy Effects 0.000 description 1
210000001161 mammalian embryo Anatomy 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000000463 material Substances 0.000 description 1
230000005226 mechanical processes and functions Effects 0.000 description 1
239000012528 membrane Substances 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
230000007102 metabolic function Effects 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
230000002438 mitochondrial effect Effects 0.000 description 1
238000002156 mixing Methods 0.000 description 1
238000004802 monitoring treatment efficacy Methods 0.000 description 1
150000002759 monoacylglycerols Chemical class 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
210000004487 mononuclear osteoclast Anatomy 0.000 description 1
210000002864 mononuclear phagocyte Anatomy 0.000 description 1
150000002772 monosaccharides Chemical class 0.000 description 1
210000004165 myocardium Anatomy 0.000 description 1
WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
229930014626 natural product Natural products 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
239000002687 nonaqueous vehicle Substances 0.000 description 1
239000002736 nonionic surfactant Substances 0.000 description 1
239000000346 nonvolatile oil Substances 0.000 description 1
235000016709 nutrition Nutrition 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
201000008482 osteoarthritis Diseases 0.000 description 1
230000010258 osteoblastogenesis Effects 0.000 description 1
230000009818 osteogenic differentiation Effects 0.000 description 1
230000000010 osteolytic effect Effects 0.000 description 1
108010071584 oxidized low density lipoprotein Proteins 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
235000019271 petrolatum Nutrition 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
239000008196 pharmacological composition Substances 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
150000008105 phosphatidylcholines Chemical class 0.000 description 1
229940067605 phosphatidylethanolamines Drugs 0.000 description 1
229940067626 phosphatidylinositols Drugs 0.000 description 1
150000008106 phosphatidylserines Chemical class 0.000 description 1
210000004180 plasmocyte Anatomy 0.000 description 1
230000004983 pleiotropic effect Effects 0.000 description 1
229920001983 poloxamer Polymers 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920000098 polyolefin Polymers 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
229940068965 polysorbates Drugs 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
208000001685 postmenopausal osteoporosis Diseases 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
210000005238 principal cell Anatomy 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
230000009993 protective function Effects 0.000 description 1
230000007115 recruitment Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
238000009256 replacement therapy Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
230000004243 retinal function Effects 0.000 description 1
238000012502 risk assessment Methods 0.000 description 1
239000011669 selenium Substances 0.000 description 1
229960001153 serine Drugs 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
210000000813 small intestine Anatomy 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
150000003408 sphingolipids Chemical class 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
238000003860 storage Methods 0.000 description 1
230000035882 stress Effects 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000003826 tablet Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
231100000041 toxicology testing Toxicity 0.000 description 1
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
230000001960 triggered effect Effects 0.000 description 1
210000000689 upper leg Anatomy 0.000 description 1
230000002485 urinary effect Effects 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
235000019154 vitamin C Nutrition 0.000 description 1
239000011718 vitamin C Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- H—ELECTRICITY
- H05—ELECTRIC TECHNIQUES NOT OTHERWISE PROVIDED FOR
- H05B—ELECTRIC HEATING; ELECTRIC LIGHT SOURCES NOT OTHERWISE PROVIDED FOR; CIRCUIT ARRANGEMENTS FOR ELECTRIC LIGHT SOURCES, IN GENERAL
- H05B41/00—Circuit arrangements or apparatus for igniting or operating discharge lamps
- H05B41/02—Details
- H05B41/04—Starting switches
- H05B41/042—Starting switches using semiconductor devices
- H—ELECTRICITY
- H05—ELECTRIC TECHNIQUES NOT OTHERWISE PROVIDED FOR
- H05B—ELECTRIC HEATING; ELECTRIC LIGHT SOURCES NOT OTHERWISE PROVIDED FOR; CIRCUIT ARRANGEMENTS FOR ELECTRIC LIGHT SOURCES, IN GENERAL
- H05B41/00—Circuit arrangements or apparatus for igniting or operating discharge lamps
- H05B41/14—Circuit arrangements
- H05B41/26—Circuit arrangements in which the lamp is fed by power derived from DC by means of a converter, e.g. by high-voltage DC
- H05B41/28—Circuit arrangements in which the lamp is fed by power derived from DC by means of a converter, e.g. by high-voltage DC using static converters
- H05B41/288—Circuit arrangements in which the lamp is fed by power derived from DC by means of a converter, e.g. by high-voltage DC using static converters with semiconductor devices and specially adapted for lamps without preheating electrodes, e.g. for high-intensity discharge lamps, high-pressure mercury or sodium lamps or low-pressure sodium lamps
- H05B41/2881—Load circuits; Control thereof
- H—ELECTRICITY
- H05—ELECTRIC TECHNIQUES NOT OTHERWISE PROVIDED FOR
- H05B—ELECTRIC HEATING; ELECTRIC LIGHT SOURCES NOT OTHERWISE PROVIDED FOR; CIRCUIT ARRANGEMENTS FOR ELECTRIC LIGHT SOURCES, IN GENERAL
- H05B41/00—Circuit arrangements or apparatus for igniting or operating discharge lamps
- H05B41/14—Circuit arrangements
- H05B41/26—Circuit arrangements in which the lamp is fed by power derived from DC by means of a converter, e.g. by high-voltage DC
- H05B41/28—Circuit arrangements in which the lamp is fed by power derived from DC by means of a converter, e.g. by high-voltage DC using static converters
- H05B41/288—Circuit arrangements in which the lamp is fed by power derived from DC by means of a converter, e.g. by high-voltage DC using static converters with semiconductor devices and specially adapted for lamps without preheating electrodes, e.g. for high-intensity discharge lamps, high-pressure mercury or sodium lamps or low-pressure sodium lamps
- H05B41/2881—Load circuits; Control thereof
- H05B41/2882—Load circuits; Control thereof the control resulting from an action on the static converter
- H—ELECTRICITY
- H05—ELECTRIC TECHNIQUES NOT OTHERWISE PROVIDED FOR
- H05B—ELECTRIC HEATING; ELECTRIC LIGHT SOURCES NOT OTHERWISE PROVIDED FOR; CIRCUIT ARRANGEMENTS FOR ELECTRIC LIGHT SOURCES, IN GENERAL
- H05B41/00—Circuit arrangements or apparatus for igniting or operating discharge lamps
- H05B41/14—Circuit arrangements
- H05B41/26—Circuit arrangements in which the lamp is fed by power derived from DC by means of a converter, e.g. by high-voltage DC
- H05B41/28—Circuit arrangements in which the lamp is fed by power derived from DC by means of a converter, e.g. by high-voltage DC using static converters
- H05B41/288—Circuit arrangements in which the lamp is fed by power derived from DC by means of a converter, e.g. by high-voltage DC using static converters with semiconductor devices and specially adapted for lamps without preheating electrodes, e.g. for high-intensity discharge lamps, high-pressure mercury or sodium lamps or low-pressure sodium lamps
- H05B41/2885—Static converters especially adapted therefor; Control thereof
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02B—CLIMATE CHANGE MITIGATION TECHNOLOGIES RELATED TO BUILDINGS, e.g. HOUSING, HOUSE APPLIANCES OR RELATED END-USER APPLICATIONS
- Y02B20/00—Energy efficient lighting technologies, e.g. halogen lamps or gas discharge lamps

Definitions

osteopenia With age the equilibrium between bone mass resorption and formation becomes altered, generally in favour of resorption, resulting in a reduction of bone mass termed osteopenia. This age related loss of equilibrium is generally due to both a decline in bone formation and more resorption. It is caused by the decrease in estrogen production in post-menopausal women, and the decline with age in the production of androgen in men (which is enzymatically converted to estrogen, a hormone that regulates bone metabolism directly and indirectly). Eventually this may lead to deterioration of bone architecture, decreased resistance to stress, bone fragility and susceptibility to fractures. These symptoms are collectively referred to as osteoporosis, which is a major health problem, especially in Western society, where it has been estimated that up to 85% of women and somewhat fewer men older than 45 years of age are at risk of developing osteoporosis.
osteoporosis may be caused by a high fat diet upregulating adipocyte differentiation at the cost of osteoblast differentiation.
This hypotheses was later substantiated by findings such as that oxidized lipids inhibit differentiation of preosteoblasts, and that minimally oxidized LDL act to inhibit osteogenic differentiation through activating PPAR alpha (Parhami F et al, J Bone Miner Res, 1999 December; 14(12):2067-78), and that PPAR gamma seems to be responsible for the decrease in osteoblasts and increase in marrow fat seen in the elderly due to its inhibition of osteoblastogenesis and stimulation of adipocyte differentiation (Ali A A et al, Endocrinology.
a PPAR gamma activator was found to inhibit stimulators of osteoclastogenesis in one publication, indirectly suggesting that PPAR gamma may decrease bone resorption (Mbalaviele G, et al, J Biol. Chem. 2000 May 12; 275(19):14388-93), but a more recent publication found direct evidence of the opposite; a PPAR gamma agonist enhanced bone loss, increased fat marrow volume, and increased bone resorption parameters (Sottile V et al Calcif Tissue Int. 2004 October; 75(4):329-37. Epub 2004 Jul. 13).
PPAR alpha and delta in regards to bone resorption, and the little information there is about PPAR gamma is conflicting, although the most direct evidence point towards a role for PPAR gamma in increasing resorption.
the compounds according to the invention are analogues of naturally occurring compounds, and as such are recognized by the same systems which process the natural compounds, including the enzymes that ⁇ - and in some cases ⁇ -oxidize natural long chain fatty acids.
the analogues differ from their naturally occurring counterparts in that they cannot be completely oxidized in this manner.
the compounds of the present invention may be administered directly to the animal by any suitable technique, including parenterally, intranasally, orally, or by absorption through the skin. They can be administered locally or systemically.
the specific route of administration of each agent will depend, e.g., on the medical history of the recipient human or animal.
Bone metabolism parameters comprise markers present in the blood such as BAP (a marker of osteogenesis), DPD (a bone resorption marker), NTX, corrected Ca, and the SOS value (an index of bone metabolism impairment).
Crosslaps has also been used to predict the rate of bone loss considering a bone loss of more than 3% per year.
Crosslapse has a specificity of 80% and a sensitivity of more than 70%, it can thus be used as a potentially useful screening parameter in the risk assessment of diseases like postmenopausal osteoporosis and Paget's disease.
Crosslaps values decreases substantially in response to replacement therapies thus suggesting its usefulness in monitoring treatment efficacy.
Crosslaps have been cleared by the FDA, and is currently used for research only, but is expected to be available for general testing soon. It is developed by Nordic bioscience diagnostics.

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Circuit Arrangements For Discharge Lamps (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

US11/989,004 2005-07-18 2006-07-10 Fatty acid analogues for equilibrating bone mineral density Abandoned US20100029973A1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
NO20053519A NO20053519L (no)	2005-07-18	2005-07-18	Anvendelse av forbindelser som omfatter fettsyrer
NO20053519		2005-07-18
PCT/NO2006/000262 WO2007011231A2 (fr)	2005-07-18	2006-07-10	Utilisation de composes comprenant des entites d'acides gras

Publications (1)

Publication Number	Publication Date
US20100029973A1 true US20100029973A1 (en)	2010-02-04

Family

ID=35295502

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
US11/989,004 Abandoned US20100029973A1 (en)	2005-07-18	2006-07-10	Fatty acid analogues for equilibrating bone mineral density
US11/989,303 Expired - Fee Related US7884554B2 (en)	2005-07-18	2006-07-27	Ignition circuit for igniting a discharge lamp and method for igniting the discharge lamp

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
US11/989,303 Expired - Fee Related US7884554B2 (en)	2005-07-18	2006-07-27	Ignition circuit for igniting a discharge lamp and method for igniting the discharge lamp

Country Status (4)

Country	Link
US (2)	US20100029973A1 (fr)
EP (1)	EP1937363A2 (fr)
NO (1)	NO20053519L (fr)
WO (1)	WO2007011231A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2166637A1 (fr)	2008-09-19	2010-03-24	Siemens Aktiengesellschaft	Agencement d'alimentation électrique pour le chauffage électrique direct d'un système de pipeline

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3108547A1 (de) *	1981-03-06	1982-10-07	Patent-Treuhand-Gesellschaft für elektrische Glühlampen mbH, 8000 München	"zuendschaltung fuer eine hochdruckmetalldampfentladungslampe"
DE3929029A1 (de) *	1989-09-01	1991-03-07	Bosch Gmbh Robert	Schaltungsanordnung zum betrieb einer gasentladungslampe
FR2693074B1 (fr)	1992-06-26	1994-08-19	Valeo Vision	Dispositif pour une lampe à décharge destiné à équiper un projecteur de véhicule et projecteur équipé d'un tel dispositif.
JP3682987B2 (ja)	1994-02-28	2005-08-17	ハリソン東芝ライティング株式会社	放電灯点灯装置及び照明装置
DE4430397A1 (de)	1994-08-26	1996-02-29	Patent Treuhand Ges Fuer Elektrische Gluehlampen Mbh	Schaltungsanordnung zum Betrieb von Niederdruckentladungslampen
ES2152010T3 (es)	1995-03-01	2001-01-16	Koninkl Philips Electronics Nv	Circuito para encender una lampara de descarga de alta presion.
EP0903967A1 (fr)	1997-09-19	1999-03-24	Quality Light Electronics S.A.S. Di Francesco Celso E C.	Dispositif d'allumage pour une lampe à décharge
JP3829507B2 (ja)	1997-12-12	2006-10-04	松下電工株式会社	電子バラストおよびｈｉｄランプ制御回路
AU7240398A (en) *	1998-05-08	1999-11-29	Rolf Berge	Use of non-beta-oxidizable fatty acid analogues for treatment of syndrome-x conditions
EP0987928B1 (fr)	1998-09-15	2003-12-17	Quality Light Electronics S.A.S. Di Francesco Celso E C.	Dispositif d' allumage à résonance pour lampes à décharge
SE9901272D0 (sv) *	1999-04-09	1999-04-09	Astra Ab	New improved formulation
EP1267890A2 (fr) *	2000-04-07	2003-01-02	The Board of Regents of The University of Texas System	Compositions uniques de phospholipides zwitterioniques et de bisphosphonates et leur utilisation sous forme de systemes d'administration de bisphosphates presentant une toxicite gastro-intestinale limitee
NO20003591L (no) *	2000-07-13	2002-01-14	Thia Medica As	Fettsyreanaloger for behandling av kreft
US7166578B2 (en) *	2000-08-24	2007-01-23	The Regents Of The University Of California	Orally administered peptides synergize statin activity
WO2004103410A1 (fr) *	2002-06-06	2004-12-02	Yissum Research Development Company Of The Hebrew University Of Jerusalem	Compositions de procedes et articles de fabrication destines a moduler la croissance osseuse
NZ537762A (en) *	2002-06-20	2007-02-23	Thia Medica As	Sulfur-containing phospholipid derivatives
NZ546349A (en) *	2003-09-29	2010-03-26	Cipla Ltd	Pharmaceutical formulation with improved stability
IL158555A0 (en) *	2003-10-22	2004-05-12	Enzymotec Ltd	Human breast milk lipid mimetic as dietary supplement
FR2862224A1 (fr) *	2003-11-14	2005-05-20	Medesis Pharma Sa	Complexes a base de strontium, pharmaceutiques et produits dietetiques
WO2006102533A2 (fr) *	2005-03-23	2006-09-28	Neopharm, Inc.	Compositions pharmaceutiquement actives a base de lipides, de conjugues nucleosides-lipides

2005
- 2005-07-18 NO NO20053519A patent/NO20053519L/no not_active Application Discontinuation
2006
- 2006-07-10 WO PCT/NO2006/000262 patent/WO2007011231A2/fr active Application Filing
- 2006-07-10 US US11/989,004 patent/US20100029973A1/en not_active Abandoned
- 2006-07-10 EP EP06769433A patent/EP1937363A2/fr not_active Withdrawn
- 2006-07-27 US US11/989,303 patent/US7884554B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
EP1937363A2 (fr)	2008-07-02
WO2007011231A3 (fr)	2007-10-18
US7884554B2 (en)	2011-02-08
US20090153071A1 (en)	2009-06-18
NO20053519D0 (no)	2005-07-18
WO2007011231A2 (fr)	2007-01-25
NO20053519L (no)	2007-01-19

Legal Events

Date

Code

Title

Description

2009-05-06

AS

Assignment

Owner name: THIA MEDICA AS,NORWAY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BERGE, ROLF;REEL/FRAME:022665/0125

Effective date: 20081004

2012-01-05

STCB

Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

Publication	Publication Date	Title
Castañeda et al.	2008	Characterization of a new experimental model of osteoporosis in rabbits
US7576053B2 (en)	2009-08-18	Methods and compositions for treating degenerative bone disorders
Rizzo et al.	1989	Dietary erucic acid therapy for X‐linked adrenoleukodystrophy
EP1075259B1 (fr)	2003-07-23	Nouveaux analogues d'acides gras destines au traitement du diabete
Firth et al.	1985	Development of hypercalcemic hyperparathyroidism after long-term phosphate supplementation in hypophosphatemic osteomalacia. Report of two cases
Monier‐Faugere et al.	1999	Intermittent and continuous administration of the bisphosphonate ibandronate in ovariohysterectomized beagle dogs: effects on bone morphometry and mineral properties
Haderslev et al.	2002	Short-term administration of glucagon-like peptide-2. Effects on bone mineral density and markers of bone turnover in short-bowel patients with no colon
Costa et al.	1981	X-linked hypophosphatemia: effect of calcitriol on renal handling of phosphate, serum phosphate, and bone mineralization
JP2006503819A (ja)	2006-02-02	骨形成を増進するための作用剤および方法
Malvi et al.	2014	High fat diet promotes achievement of peak bone mass in young rats
Hosking	1990	Advances in the management of Paget’s disease of bone
Fox et al.	2007	Treatment of skeletally mature ovariectomized rhesus monkeys with PTH (1‐84) for 16 months increases bone formation and density and improves trabecular architecture and biomechanical properties at the lumbar spine
Kishi et al.	1998	Bone responses at various skeletal sites to human parathyroid hormone in ovariectomized rats: effects of long-term administration, withdrawal, and readministration
HU229613B1 (en)	2014-03-28	Oral administration of parathyroid hormone and calcitonin
Pawlak et al.	2018	LP533401 restores bone health in 5/6 nephrectomized rats by a decrease of gut-derived serotonin and regulation of serum phosphate through the inhibition of phosphate co-transporters expression in the kidneys
US20100029973A1 (en)	2010-02-04	Fatty acid analogues for equilibrating bone mineral density
Paris et al.	2004	Plasma GLP-2 levels and intestinal markers in the juvenile pig during intestinal adaptation: effects of different diet regimens
Fournier et al.	2014	Low calcium-phosphate intakes modulate the low-protein diet-related effect on peak bone mass acquisition: a hormonal and bone strength determinants study in female growing rats
Wezeman et al.	2007	Vitamin D and ibandronate prevent cancellous bone loss associated with binge alcohol treatment in male rats
Ching et al.	1990	Trabecular bone remodeling and bone mineral density in the adult cat during chronic dietary acidification with ammonium chloride
Hahn	2009	Metabolic bone disease
WO2007011232A2 (fr)	2007-01-25	Utilisation d'agents de clarification lipidiques
Puzio et al.	2014	Fundectomy, antrectomy and gastrectomy influence densitometric, tomographic and mechanical bone properties as well as serum ghrelin and nesfatin-1 levels in rats.
Ito et al.	2003	Preventive effects of sequential treatment with alendronate and 1α-hydroxyvitamin D3 on bone mass and strength in ovariectomized rats
Toh et al.	1983	Effect of calcitonin treatment on the natural course of bone demineralization in Paget's disease